TipRanks
SK Biopharmaceuticals Co., Ltd. (KR:326030)
:326030
South Korea Market
326030
SK Biopharmaceuticals Co., Ltd.
RESEARCH TOOLSreports
Want to see KR:326030 full AI Analyst Report?

SK Biopharmaceuticals Co., Ltd. (326030) Income Statement

― Followers

SK Biopharmaceuticals Co., Ltd. Income Statement

Last quarter (Q2 2026), SK Biopharmaceuticals Co., Ltd.'s total revenue was ₩247.37B, an increase of 40.33% from the same quarter last year. In Q2, SK Biopharmaceuticals Co., Ltd.'s net income was ₩85.06B. See SK Biopharmaceuticals Co., Ltd.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
₩ 706.74B₩ 547.60B₩ 354.89B₩ 246.18B₩ 418.64B
Gross Profit
₩ 651.67B₩ 504.50B₩ 320.81B₩ 208.41B₩ 396.31B
Operating Expenses
₩ 447.73B₩ 408.16B₩ 358.33B₩ 339.49B₩ 301.35B
Depreciation and Amortization
₩ 16.95B₩ 17.43B₩ 15.32B₩ 12.98B₩ 11.64B
EBITDA
₩ 220.89B₩ 100.71B₩ -8.73B₩ -125.77B₩ 167.68B
Operating Income
₩ 203.94B₩ 96.34B₩ -20.63B₩ -131.08B₩ 94.96B
Other Income/Expenses
₩ -53.05B₩ -23.74B₩ -23.23B₩ -11.39B₩ -23.68B
Pretax Income
₩ 150.88B₩ 72.60B₩ -43.86B₩ -142.47B₩ 71.28B
Net Income
₩ 266.95B₩ 240.74B₩ -32.88B₩ -139.43B₩ 64.85B
Per Share Metrics
Basic EPS
₩ 3.41K₩ 3.07K₩ -419.89₩ -1.78K₩ 828.03
Diluted EPS
₩ 3.41K₩ 3.07K₩ -419.89₩ -1.78K₩ 828.03
Weighted Average Shares Outstanding
 78.31M 78.31M 78.31M 78.31M 78.31M
Weighted Average Shares Outstanding (Diluted)
 78.31M 78.31M 78.31M 78.31M 78.31M
Currency in KRW

SK Biopharmaceuticals Co., Ltd. Earnings and Revenue History